S1P receptor modulating compounds and use thereof

Details S1P receptor modulating compounds and use thereof S1P receptor modulating compounds and use thereof

2006-07-24

2010-12-21

Kosack, Joseph R (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S233500, C514S320000, C514S422000, C514S469000, C544S153000, C546S196000, C548S517000, C548S953000, C549S467000

Reexamination Certificate

active

07855193

ABSTRACT:
The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

REFERENCES:
patent: 3329781 (1967-07-01), Wiser
patent: 4767896 (1988-08-01), Nigg et al.
patent: 5145865 (1992-09-01), Fujii et al.
patent: 5614531 (1997-03-01), Juraszyk et al.
patent: 5880284 (1999-03-01), Himmelsbach et al.
patent: 6384061 (2002-05-01), Lee et al.
patent: 6411326 (2002-06-01), Tabata
patent: 2002/0156074 (2002-10-01), Barvian et al.
patent: 2002/0183519 (2002-12-01), Nar et al.
patent: 2005/0014725 (2005-01-01), Mi et al.
patent: 2005/0113283 (2005-05-01), Solow-Cordero et al.
patent: 2006/0135786 (2006-06-01), Saha et al.
patent: 2007/0173487 (2007-07-01), Saha et al.
patent: 2008/0015177 (2008-01-01), Saha et al.
patent: 2008/0027036 (2008-01-01), Burli et al.
patent: 2008/0064677 (2008-03-01), Saha et al.
patent: 1 553 075 (2005-07-01), None
patent: 10-204059 (1998-08-01), None
patent: 10-204059 (1998-08-01), None
patent: 02064616 (2002-08-01), None
patent: 03061567 (2003-07-01), None
patent: 03062252 (2003-07-01), None
patent: 03105771 (2003-12-01), None
patent: 2004048383 (2004-06-01), None
patent: 2004062663 (2004-07-01), None
patent: 2004113330 (2004-12-01), None
patent: 2005020882 (2005-03-01), None
patent: 2006064757 (2006-06-01), None
patent: 2007061458 (2007-05-01), None
patent: 2007109334 (2007-09-01), None
patent: WO 2007/109330 (2007-09-01), None
patent: WO 2009/038759 (2009-03-01), None
Traynor et al., 1995, “Modulation by μ-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells,” Molecular Pharmacology, 47, 848-854.
Zemann et al., 2006, “Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720,” Blood, 107(4), 1454-1458.
Pan et al., 2006, “A monoselective sphingosine-1-phospate receptor-1 agonist preents allograft rejection in a stringent rat heart transplantation model,” Chemistry & Biology, 13, 1227-1234.
Abdel-Rahman, T.M., 1998, “Synthesis and Antimicrobial Activity of Some new Thiophene-2-Sulphonyl, Amino Acids and Their Peptide Derivatives,” Mans.Sci.Bull. (A Chem.) vol. 25 (1), Jun. 1998.

Affiliated with

Also associated with

Rating

S1P receptor modulating compounds and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with S1P receptor modulating compounds and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S1P receptor modulating compounds and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4159685